ACTG 175 confirms the benefit of antiretroviral therapy in persons starting between 200-500 CD4 cells and before the development of AIDS (cf. ACTG 016, 109). ACTG 175 shows for the first time that initiating antiretroviral therapy at this time (CD4…
House Republican Plan Calls for AIDS Research Dollars to Be Mixed Into Pot For All to Avail Themselves Of The OAR as paper tiger In 1993, dozens of AIDS organizations and hundreds of AIDS researchers joined together to push for…
Controversial Nucleoside Study Awakens To A World Strangely Disaffected By Its Prepackaged Proclamation Beware the Composite Endpoint "Endlessly scrutinizing mediocrity" is how the 3,000 patient combination-versus- monotherapy mega-trial ACTG 175 was characterized in a July 29, 1991 issue of ACT…
Feel Good Merck Meeting Leaves Everybody Agreeing, But Brazil Study Bodes Ill for the Future On June 23 1995, members of TAG met with statisticians from Merck and outside statistical experts to discuss the methodological assumptions of its Phase III…
New Model of Immune Defense to HIV Shows How Nature of Response Might Determine Eventual Outcome Sloppy RT, Bane of All A provocative research paper initially published in the international weekly science journal Nature ("Antigenic oscillations and shifting immunodominance in…
With Two Down And Integrase On Deck, AIDS Research Team Hopes For a Hit--Or Will It Be 'Three Up, Three Down?' Third and Final Enzymatic Target The HIV genome encodes for three enzymes that are necessary for infection and replication…
FDA's Oncological Drug Advisory Committee Recommends DOX-SL for Accelerated Approval--But Not Without A Fight 'Nothing but ugly' Michael Marco reports back from FDA-land, where there is always a story to tell, and usually more than one way to tell it…
FDA Just Says "No" To Salk Immunogen. The illustrious Dr. Jonas Salk and officials of his Immune Response Corp. appeared before an FDA advisory committee on 26 January seeking approval for large-scale Phase III efficacy trials of its envelope depleted…
Merck's Scientists Cave In To The Vogue of Surrogate Marker Endpoint Trials, Accelerated Approval And Quick Cash Dr. Emini's Gamble David Barr, David Gilden (GMHC), Mark Harrington, Michael Ravitch, Theo Smart (TAG), Ben Cheng, Marty Delaney, Joel Thomas (Project Inform),…
Inauspicious Debut for HIV Specific CTLs; New Concerns about IL-12; Neutralizing Approaches for "Bad" Cytokines; Parke-Davis Targets Cellular Factors Souped-Up Abs from LTNPs The Clinical Immunology Society's 2nd HIV Immune-based Therapies Workshop was held in Baltimore on January 27-29. Attendance…